NVCT

Healthcare Biotechnology

Nuvectis Pharma, Inc.

$21.92

+1.22 +5.91% today

Price History

Not enough data

Key Stats

Market Cap

715.56M

Avg Volume

230,100

EPS

-$1.32

52W High

$29.28

52W Low

$5.55

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-22.83

P/B Ratio

64.47

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(214.6%)

Return on Assets

(73.1%)

Liquidity & Leverage

Current Ratio

1.68

Quick Ratio

1.67

Total Cash

22.16M

Total Debt

About

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.